1 Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
2 Neurobiology of Disease Graduate Program, Mayo Graduate School, Mayo Clinic College of Medicine, Rochester, MN, USA.
3 Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.
4 Department of Neurology, Mayo Clinic, Rochester, MN, USA.
5 Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
6 National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. wardme@nih.gov.
7 Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. wardme@nih.gov.
8 Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA. zhang.yongjie@mayo.edu.
9 Neurobiology of Disease Graduate Program, Mayo Graduate School, Mayo Clinic College of Medicine, Rochester, MN, USA. zhang.yongjie@mayo.edu.
10 Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA. petrucelli.leonard@mayo.edu.
11 Neurobiology of Disease Graduate Program, Mayo Graduate School, Mayo Clinic College of Medicine, Rochester, MN, USA. petrucelli.leonard@mayo.edu.
This letter demonstrates the potential of novel cryptic proteins resulting from TAR DNA-binding protein 43 (TDP-43) dysfunction as markers of TDP-43 pathology in neurodegenerative diseases.